Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06932783 · ClinicalTrials.gov registry record · NA
Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis
A NA study of Cirrhosis, sponsored by University of Michigan.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06932783: Recruiting NA study of Cirrhosis, sponsored by University of Michigan.
NCT06932783 is a NA study of Cirrhosis that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 30 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06932783, a NA study of Cirrhosis, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to better understand how the study team can treat pain for people with cirrhosis and depression. Enrolled participants on this feasibility study will be randomized to Transcutaneous Electrical Acustimulation (TEA) or sham TEA.
Primary Outcome
There are 7 questions that will be completed regarding the participant's experience with the study. There are six questions that participants will select strongly agree (5) - strongly disagree (1), with a range of 6-30. Additionally, participant's select from not very likely (1) -extremely likely (10). The last scale 1-10 asks "on a scale from 1-10, where 1 is not very likely and 10 is extremely likely, I am likely to recommend using the TEA device to a friend, colleague, or family member with
Conditions Studied
Interventions
- DEVICE Transcutaneous Electrical Acustimulation (TEA)
- DEVICE Sham Transcutaneous Electrical Acustimulation (TEA)
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2027-07 |
| Phase | NA |
What NCT06932783 shows while recruiting
NCT06932783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Transcutaneous Electrical Acustimulation (TEA) is the first listed.
NCT06932783 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06932783 about?
NCT06932783 is a clinical study titled "Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis". This study is being done to better understand how the study team can treat pain for people with cirrhosis and depression. Enrolled participants on this feasibility study will be randomized to Transcutaneous Electrical Acustimulation (TEA) or sham TEA.
What is the current status of trial NCT06932783?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-07-22. Estimated completion is 2027-07.
What conditions does trial NCT06932783 study?
This clinical trial studies the following conditions: Cirrhosis.
What interventions are being tested in trial NCT06932783?
The interventions under investigation include: Transcutaneous Electrical Acustimulation (TEA) (DEVICE), Sham Transcutaneous Electrical Acustimulation (TEA) (DEVICE).
Who is sponsoring clinical trial NCT06932783?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06932783 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06932783's enrollment target sits among peer trials
30 31st of 53 higher than 13 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
CirrhosisRx CDS System
RECRUITING · NA
-
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
RECRUITING · NA
-
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI